At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 2,030 enrolled
Drug / intervention
Mirabegron +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
In Brief
A Phase 3 clinical trial evaluating Mirabegron and Placebo for Urinary Bladder, Overactive. Completed, enrolled 2,030 participants across 151 sites in 11 countries.
Detailed Summary
The study is intended to test efficacy, safety and tolerability of two doses of once daily (qd) Mirabegron against placebo to treat patients with symptoms of overactive bladder.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrinary Bladder, Overactive
CountriesCanada, Czechia, Denmark, Finland, Germany, Hungary, Norway, Slovakia, Spain, Sweden, United States
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2009
First PostedJun 2009
Primary CompletionApr 2010
TodayJul 2026
First PostedJun 3, 2009
Enrollment StartApr 28, 2009
Primary CompletionApr 27, 2010
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 17.1 years ago
Interventions
Mirabegrondrug
Mirabegron tablets
Placebodrug
Matching mirabegron placebo tablets.